Helsana HealthInvest

Yazen is a digital healthcare provider focused on delivering personalized weight loss programs, primarily targeting middle-aged men dealing with obesity and potential testosterone deficiencies. The company connects users with a multidisciplinary team of professionals, including doctors, psychologists, dietitians, and personal trainers, to develop customized weight management plans. By leveraging data-driven insights, Yazen incorporates lifestyle changes and, when necessary, medical treatments to enhance both physical and mental well-being. The platform's holistic approach aims to empower individuals to achieve sustainable health improvements through expert guidance and support.

Hedera Dx is a healthcare venture based in Epalinges, Vaud, established on July 1, 2021, that develops a liquid biopsy solution aimed at simplifying tumor profiling for hospital labs. This technology provides clinicians with a streamlined experience for accessing information and conducting liquid biopsy tests, which are essential for early cancer detection, therapy selection, and monitoring recurrence. By addressing challenges such as IVD compliance, privacy infrastructure, and validation, Hedera Dx enhances the efficiency of existing software workflows while offering key capabilities that were previously lacking. The company's innovations provide medical professionals with new opportunities to reduce cancer mortality and healthcare costs.

Kenbi is a nurse-centric outpatient care company focused on enhancing healthcare delivery by supporting nurses and addressing gaps in the system. It offers outpatient care management services that leverage technology and a collegial organizational structure to organize local care teams. These teams provide at-home services, which may include medical care covered by insurance, household assistance, advice, and companionship. By streamlining operations and reducing bureaucratic burdens, Kenbi enables healthcare practitioners to devote more time to patient care, thus improving the overall experience for patients and their families.

Entyre GmbH, founded in 2017 and based in Hamburg, Germany, operates an online platform that assists patients and caregivers in navigating bureaucratic processes within the healthcare system. The company utilizes proprietary data and algorithms to enhance decision-making for patients, doctors, and insurance companies by providing technical solutions that identify and rectify incorrect supplies. By evaluating outpatient care, Entyre enables users to better manage their healthcare needs and address the challenges posed by demographic changes. The company also offers contact information, including email, telephone numbers, and physical addresses, on its website to facilitate inquiries.

Humanoo is a digital health platform aimed at enhancing the physical and mental well-being of employees and insurance clients. The platform offers customized programs and innovative eHealth solutions in areas such as fitness, physiotherapy, yoga, mindfulness, and nutrition, helping users achieve their health goals. By providing comprehensive decentralized analysis, Humanoo enables companies and insurers to gain insights into the health of their employees or clients, facilitating measurable improvements. The team, comprised of 65 professionals from 15 countries, includes software developers, designers, marketing and sales specialists, as well as health and wellness experts such as sports scientists, nutritionists, yoga instructors, and physiotherapists. Humanoo's mission is to motivate individuals to maintain a healthy lifestyle and improve their overall productivity.

EPha.ch is a startup emerging from the University Hospital Zurich and the University of Zurich, focused on clinical pharmacology. The company comprises an interdisciplinary team of specialists, including pharmacists and computer scientists, who possess extensive expertise in drug therapy. EPha.ch has developed a digital AI-powered assistant that aims to prevent medication errors and enhance patient safety. By utilizing artificial intelligence and advanced algorithms, the platform evaluates the safety of polypharmacy and provides personalized medication alternatives and guidance. This enables healthcare providers to analyze and optimize medication plans for patients, ensuring timely and informed decision-making based on comprehensive drug information.

Hedera Dx is a healthcare venture based in Epalinges, Vaud, established on July 1, 2021, that develops a liquid biopsy solution aimed at simplifying tumor profiling for hospital labs. This technology provides clinicians with a streamlined experience for accessing information and conducting liquid biopsy tests, which are essential for early cancer detection, therapy selection, and monitoring recurrence. By addressing challenges such as IVD compliance, privacy infrastructure, and validation, Hedera Dx enhances the efficiency of existing software workflows while offering key capabilities that were previously lacking. The company's innovations provide medical professionals with new opportunities to reduce cancer mortality and healthcare costs.